In3Bio

MHRA Approves Phase I/II Clinical Trial of IN3BIO Vaccine to Improve Outcomes for Colorectal Cancer Patients

March 9, 2022 – IN3BIO Research Limited, a leader in developing cancer treatments that, based upon clinical data, show significant promise and appear to be more tolerable for patients, announces today that it has received Clinical Trial Application approval from the British Medicines & Healthcare Products Regulatory Agency (MHRA) to initiate a Phase I/II clinical …

MHRA Approves Phase I/II Clinical Trial of IN3BIO Vaccine to Improve Outcomes for Colorectal Cancer Patients Read More »

IN3BIO gains approval for Phase I/II clinical trial

June 8, 2021 – IN3BIO Research Limited announced today that the company has received the Clinical Trial Application approval from the Bulgarian Drug Agency and Ethical Committee to initiate a Phase I/II clinical trial of its colorectal cancer vaccine in Bulgaria.

Anti-epidermal growth factor vaccine antibodies increase the antitumor activity of kinase inhibitors in ALK and RET rearranged lung cancer cells

Advanced NSCLC patients harboring EML4-ALK and CCDC6-RET rearrangements derive benefit from treatment with ALK and RET TKIs but not immune checkpoint inhibitors. New immunotherapeutic approaches, such as immunization against growth factors, can be of particular interest for combination treatment in these patients. Here, we investigated the effects of anti-EGF antibodies generated by vaccination (anti-EGF VacAbs), …

Anti-epidermal growth factor vaccine antibodies increase the antitumor activity of kinase inhibitors in ALK and RET rearranged lung cancer cells Read More »

Anti-EGF antibodies generated by vaccination significantly improve the activity of kinase inhibitors in preclinical models

Epidermal Growth Factor Receptor (EGFR) signaling system is frequently unbalanced in cancer and the ligand Epidermal Growth Factor (EGF) could be an attractive target. KRAS mutated and EML4-ALK fusion tumors are treated with several compounds but resistance invariably appears. Previously we described the biological effects of EGFR antibodies raised by a “cancer vaccine” against human EGF in EGFR mutated NSCLC cells(1,2).

Anti-EGF antibodies increase the effect of ALK and MEK inhibitors in ALK and KRAS NSCLC and CRC cell lines

Epidermal Growth Factor Receptor (EGFR) signaling is frequently unbalanced in non-small-cell lung cancer (NSCLC) and the ligand Epidermal Growth Factor (EGF) could be an attractive target. A “cancer vaccine” against human EGF has demonstrated efficacy in a phase III trial including unselected NSCLC patients, but little was known about the mechanisms involved in the effects of the anti- EGF antibodies generated by vaccination (anti-EGF VacAbs) or their activity in tumor cells with different genetic backgrounds (1-3)

Antitumor effects of anti-EGF antibodies generated by vaccination in NSCLC tumor cells

Epidermal unbalanced in non-small-cell lung cancer (NSCLC) and the ligand Epidermal Growth Factor (EGF) could be an attractive target. A “cancer vaccine” against human EGF has demonstrated efficacy in a phase III trial including unselected NSCLC patients, but little was known about the mechanisms involved in the effects of the anti-EGF antibodies generated by vaccination (anti-EGF VacAbs) or their activity in tumor cells with different genetic backgrounds (1-3)